News
Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...
18h
MedPage Today on MSNCVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' BankruptcyMany patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...
Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for ...
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
As a Biden administration ban on so-called “junk fees” took effect Monday, Ticketmaster said it would start displaying the ...
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...
NRG Energy has agreed to acquire LS Power's portfolio of natural gas generation facilities and power plant platform in a cash-and-stock deal with an enterprise value of about $12 billion. The media ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results